ARKG vs HQL
ARK Genomic Revolution ETF against abrdn Life Sciences Investors: cost, size, returns, what they hold and how much of it is the same.
Fee gap
—
same fee
1-year return gap
39.9 pts
ARKG is ahead
Larger fund
ARKG
$2.0B
Side by side
| ARKG | HQL | |
|---|---|---|
| Fund | ARK Genomic Revolution ETF | abrdn Life Sciences Investors |
| Issuer | ARK | abrdn |
| Category | Biotech & Health Innovation | Biotech & Health Innovation |
| Expense ratio | 0.75% | — |
| Assets | $2.0B | $546M |
| Average daily dollar volume | $272M | $2.3M |
| Listed | Oct 31, 2014 | May 1, 1992 |
| FrenzyCap score | 57 | 54 |
| 1-month return | −6.0% | −8.2% |
| 3-month return | +26.6% | −6.8% |
| Year to date | +65.2% | +7.0% |
| 1-year return | +46.6% | +6.7% |
| 30-day volatility | 53.9% | 30.6% |
| Worst drawdown, 1 year | −27.5% | −26.0% |
| Trailing 12-month yield | — | — |
| Holdings | 35 | — |
| Top 10 weight | 58.5% | — |
| Look-through P/E | — | — |
| Holdings vs fair value | +6.4% | — |
| Holdings above 200-day average | 84% | — |
| Net flow, latest 3 reported months | −$3.3M thru Jul 2026 | — |
| 30-day implied volatility | 55.5% | — |
| Holdings as of | as of Oct 22, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
More: full overlap table · ARKG holdings · HQL holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.